MedTrace Logo

Statins, Cholesterol and Cognitive Decline in Alzheimer's

NCT06635252 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-05-02

No results posted yet for this study

Summary

Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.

Conditions

  • Alzheimer Dementia
  • Statins

Interventions

DRUG

STA 4783

Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-03-01
Completion
2025-03-01
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06635252 on ClinicalTrials.gov